Patents by Inventor Zhibing Zheng

Zhibing Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10131643
    Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: November 20, 2018
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
  • Patent number: 10071994
    Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof.
    Type: Grant
    Filed: May 25, 2015
    Date of Patent: September 11, 2018
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Junhai Xiao, Qi Sun, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang, Ruiyuan Cao
  • Patent number: 10023565
    Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang, Lili Wang
  • Publication number: 20180185376
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.
    Type: Application
    Filed: June 28, 2016
    Publication date: July 5, 2018
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Junhai XIAO, Boqun LYU, Hongqiang WANG, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xinbo ZHOU, Xingzhou LI, Xiaokui WANG
  • Publication number: 20180179193
    Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof. The compound has an effect of regulatory of bacterial quorum sensing, and is useful for preventing and/or treating a disease caused by infection of a bacterium.
    Type: Application
    Filed: May 25, 2015
    Publication date: June 28, 2018
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Junhai XIAO, Qi SUN, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xingzhou Li, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
  • Publication number: 20180134653
    Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 17, 2018
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Junhai XIAO, Lili WANG, Long LONG, Wei LI, Haoming LUO, Feifei LI, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
  • Patent number: 9914711
    Abstract: The invention relates to a compound of formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 13, 2018
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Junhai Xiao, Mingming Zhao, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Guoming Zhao, Xinbo Zhou, Xiaokui Wang, Wei Chen
  • Publication number: 20180044321
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 15, 2018
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song LI, Yanqun ZENG, Junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG
  • Publication number: 20170362261
    Abstract: The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 21, 2017
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Xingzhou LI, Wu ZHONG, Zhibing ZHENG, Junhai XIAO, Xinbo ZHOU, Yunde XIE, Xiaokui WANG, Lili WANG, Wei CHEN, Fei XIE
  • Patent number: 9840489
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 12, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Patent number: 9718770
    Abstract: The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 1, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Publication number: 20170190656
    Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.
    Type: Application
    Filed: May 20, 2015
    Publication date: July 6, 2017
    Applicant: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China
    Inventors: Song LI, Junhai XIAO, Lili WANG, Long LONG, Wei LI, Haoming LUO, Feifei LI, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
  • Patent number: 9630957
    Abstract: Provided are a compound of formula I which can be used as a drug against small RNA virus infections, and optical isomers, pharmaceutically acceptable salts, solvates or hydrates thereof. Also provided are the preparation method of the compound, the method for using the compound for treating bacterial infections and the use of the compound in the preparation of a drug for preventing and/or treating viral diseases caused by small RNA viruses.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 25, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Junhai Xiao, Xian Zhang, Wu Zhong, Zhibing Zheng, Lili Wang, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang
  • Patent number: 9630939
    Abstract: A derivative of homoserine lactone represented by formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: April 25, 2017
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
    Inventors: Song Li, Junhai Xiao, Mingming Zhao, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Guoming Zhao, Xinbo Zhou, Xiaokui Wang, Wei Chen
  • Patent number: 9522891
    Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 20, 2016
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
    Inventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
  • Patent number: 9518008
    Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: December 13, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu
  • Publication number: 20160340326
    Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.
    Type: Application
    Filed: July 4, 2014
    Publication date: November 24, 2016
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Xingzhou LI, Wu ZHONG, Zhibing ZHENG, Junhai XIAO, Xinbo ZHOU, Yunde XIE, Xiaokui WANG, Lili WANG, Wei CHEN, Fei XIE
  • Publication number: 20160333002
    Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 17, 2016
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song LI, Yanqun ZENG, Junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG, Lili WANG
  • Patent number: 9493453
    Abstract: Provided are piperazinyl pyrimidine derivatives of formula I having CCR4 antagonism, and the preparation method, pharmaceutical composition and use thereof in the preparation of a medicament. The medicament is useful for the treatment and prevention of CCR4-related diseases.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: November 15, 2016
    Assignees: The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. CHINA, PEKING UNIVERSITY
    Inventors: Song Li, Ying Wang, Junhai Xiao, Dalong Ma, Hongwei Gong, Hui Qi, Lili Wang, Xiaomei Ling, Zhibing Zheng, Yang Zhang, Wu Zhong, Meina Li, Yunde Xie, Enquan Xu, Xingzhou Li, Jing Ma, Guoming Zhao, Xinbo Zhou, Xiaokui Wang, Hongying Liu
  • Publication number: 20160318896
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song LI, Yanqun ZENG, Junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG